Table 1.

Clinical baseline characteristics of AD patients with rhinitis.

	Age	Sex	Disease	Treatment	Treatment Deatails	EASI	TNSS	DLQI	VAS (mm)	TARC (pg/ml)	Total IgE (kUA/L)	Der p s-IgE (kUA/L)	Der p s-IgG4 (mgA/L)
			Duration (year)	Duration (year)
1	25	Female	22	1.5	Topical steroid Antihistamines	16.5	11	16	70	361	1761.1	135.6	0.1
2	45	Male	16	5	Topical steroid Topical calcineurin inhibitors	13.2	1	1	0	2522	23207.3	2740	0.5
3	47	Male	23	8	Topical steroid	22.8	7	10	60	988	5137	80.3	0.2
4	46	Male	42	5	Topical steroid Topical calcineurin inhibitors	27.3	5	5	20	3039	5467	160	1.4
5	39	Female	36	2.5	Topical steroid Antihistamines	14.2	4	8	80	670	1146.4	78.6	0.2
6	30	Male	14	1	Topical steroid Topical calcineurin inhibitors	5.9	9	13	50	310	7543.8	550	0.6
7	45	Male	45	7	Topical steroid Topical calcineurin inhibitors	4.1	4	4	40	532	348.6	11.2	0.1

Table 1 shows seven registered patients. Patient No. 3 had asthma and patient No. 5 had cholinergic urticaria and asthma. Values of the EASI, TARC, DLQI, TNSS, total IgE, specific-IgE and specific-IgG4 at baseline of this study are shown. The median disease duration was 23 (14–45) (year), The median treatment duration was 5 (1.5–8) (year), The median EASI was 14.2 (4.1–27.3), the median TNSS was 5 (1–11), the median DLQI was 8 (1–6), the median VAS was 50 (0–80) (mm), the median total serum IgE was 5137 (348.6–23207.3) (kUA/L), the median TARC was 670 (310–3039) (pg/ml), the median Der p s-IgE was 135.6 (11.2–2740) (kUA/L), the median Der p s-IgG4 was 0.22 (0.14–1.47) (mgA/L), the median Der f s-IgE was 182.6 (10–1480) (kUA/L) and the median Der f s-IgG4 was 0.31 (0.12–1.78) (mgA/L).

DLQI: Dermatology Life Quality Index; EASI: Eczema area and severity index; TARC: Thymus and activation-regulated chemokine; TNSS: Total nasal symptom score; VAS: Pruritus Visual Analogue Scale.